Skip to search formSkip to main contentSkip to account menu

CCI 779

Known as: Rapamycin Analog CCI-779, Cell Cycle Inhibitor 779, CCI-779 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

temsirolimus

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Comorbidities Drive Outcomes for Both Malignancy-Associated and Non-Malignancy-Associated Hemophagocytic Syndrome.
2013
2013
The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells
BackgroundLiver cancer is one of the most frequent cancers in the world. Targeted therapy of cancer with specific inhibitors is… 
2007
2007
CCI-779 plus Cisplatin Is Highly Effective against Human Melanoma in a SCID Mouse Xenotranplantation Model
Background: This study set out to investigate the antitumor effects of a treatment strategy combining the mTOR inhibitor CCI-779… 
2007
2007
330 POSTER Preclinical evidence for the effectiveness of mTOR inhibitor, nanoparticle albumin-bound (nab®) rapamycin as an anticancer agent
2006
2006
The mTOR Inhibitor Temsirolimus (CCI-779) Induces Cell Cycle Arrest and Autophagy in Hodgkin Lymphoma (HL) Cell Lines and Enhances the Effect of the PI3-Kinase Inhibitor LY294002.
The PI3K/AKT/mTOR pathway is frequently activated in a variety of cancers giving hope that that this pathway may prove to be a… 
2006
2006
The mTOR inhibitor CCI-779 (temsirolimus) downregulates p21 and induces cell cycle arrest and autophagy in mantle cell lymphoma (MCL).
7573 Background: Mantle cell lymphoma (MCL) is a distinct type of B-cell lymphoma associated with transient response to… 
Review
2005
Review
2005
N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis
1505 Background: CCI-779 is a small molecule inhibitor of the mammalian target of rapamycin (mTOR), and represents a rational… 
2004
2004
A Phase II Study of Temsirolimus (CCI-779) in Patients with Advanced Leukemias.
Temsirolimus (CCI-779, Wyeth Pharmaceuticals) has been shown to inhibit proliferation of a variety of tumors and induce G1 cell… 
2004
2004
CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium
7523 Background: CCI-779 mTOR kinase inhibitor is a targeted chemotherapeutic agent that inhibits malignant cell cycle… 
2004
2004
NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM).
1503 Background: CCI-779 is a small molecule inhibitor of the mammalian target of rapamycin (mTOR). mTOR is a rational… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)